



PRESS RELEASE

LAC Med's IPO oversubscribed by 12.6 times

- *Receives total applications worth RM204.6 million for public tranche*
- *Adopts dividend policy of distributing at least 30.0% of annual audited profit after tax attributable to shareholders*
- *To list on the Main Market of Bursa Malaysia Securities Berhad on 10 December 2025*

Selangor, Malaysia, 1 December 2025 - Leading medical devices and integrated solutions provider, LAC Med Berhad ("LAC Med" or "the Group") has garnered strong interest for its Initial Public Offering ("IPO") on the Main Market of Bursa Malaysia Securities Berhad ("Bursa Securities"), with the public tranche oversubscribed by 12.6 times.

LAC Med received a total of 6,649 applications for approximately 272.8 million shares, amounting to approximately RM204.6 million, compared with the 20.0 million shares made available for application by the Malaysian public.

The IPO entails a total of approximately 104.2 million ordinary shares in LAC Med at an IPO price of RM0.75 per share. Upon listing, the enlarged share capital of LAC Med will consist of 400.0 million shares, translating into an enlarged indicative market capitalisation of RM300.0 million.

Out of the total, approximately 74.2 million are new ordinary shares ("Public Issue Shares"). Of these new shares, approximately 4.2 million are reserved for Eligible Persons, 20.0 million are allocated to the Malaysian public, and 50.0 million are offered under the Institutional Offering to Bumiputera investors approved by the Ministry of Investment, Trade and Industry of Malaysia ("MITI").

In addition, the IPO exercise comprises up to 30.0 million Offer for Sale Shares for institutional and selected investors through bookbuilding. The Offer for Sale Shares portion attracted overwhelming demand, achieving a subscription rate of more than 10 times.

"The oversubscription of our IPO by both institutional investors and the Malaysian public reflects strong confidence in LAC Med's expansion strategy and long-term prospects. We remain committed to push for wider adoption of advanced medical devices and AI-powered clinical support systems by our clientele to accelerate decision-making, streamline workflows, and improve diagnostic capabilities.

As we move into the next phase of growth, we will continue to reinforce our role as a trusted medical partner in Malaysia's healthcare sector by broadening our range of diversified products and service capabilities, while progressively expanding our presence in Indonesia to support long-term revenue growth."

Mr. Liew Yoon Poh ("刘任堡")

Group Chief Executive Officer of LAC Med Berhad

LAC Med is a turnkey provider of end-to-end medical device and integrated solutions, offering services from initial preliminary planning up to post-installation support services. The Group's capabilities include facility design and infrastructure planning, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, as well as training, technical support and ongoing maintenance.



LAC Med also provides software and systems integration for healthcare facilities, connecting various medical devices to facilitate data management and analytics; AI-powered clinical decision support systems; display; and storage.

With an established track record built over two decades, LAC Med has served 217 hospitals nationwide, commanding a market coverage of 58%. These healthcare service providers include *IHH Healthcare Group, Sunway Healthcare Group, Columbia Asia, MAHSA Hospital*, and many more. Beyond hospitals, the Group has also serviced over 800 clinics across Malaysia.

LAC Med also aims to leverage its extensive experience to accelerate its expansion into Indonesia. According to the Indonesian Ministry of Health, the country had 3,228 hospitals, 10,268 public health centres, and 20,693 private clinics in 2024. The scale of Indonesia's healthcare network provides a substantial demand base for medical device distribution, positioning LAC Med to capture new opportunities in the region.

In line with its objective of enhancing shareholder value, LAC Med remains committed to providing consistent returns to its investors. The Group intends to adopt a dividend policy to distribute at least 30% of its annual net profit, enabling shareholders to benefit from the Group's performance.

LAC Med is slated for listing on the Main Market of Bursa Malaysia on 10 December 2025.

RHB Investment Bank Berhad is the Principal Adviser, Joint Underwriter and Sole Placement Agent for the IPO, while Alliance Islamic Bank Berhad is the Joint Underwriter.



Established in 2004, LAC Med is a leading medical devices and integrated solutions provider. Through its subsidiaries, LAC Med has established itself as a trusted partner to service providers in the healthcare sector. LAC Med has installed an extensive base of more than 2,500 units of medical equipment and supports over 300 active clients across Malaysia's healthcare sector, including private and public healthcare institutions, university hospitals, local health offices, medical device suppliers and concessionaire companies.

LAC Med's competencies extend from initial preliminary planning and facility design, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, to post-installation support services including training, technical support and maintenance services.

As an authorised distributor in Malaysia and Indonesia, LAC Med supplies and installs third-party brands of medical devices comprising medical equipment and associated products, which include medical consumables and provision of software and system integration.

LAC Med represents leading international medical brands including Samsung and Philips, with which it holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also been appointed as an authorised distributor for Stryker, LG, Epson, SwiftMR, Abbott, annalise.ai, Alpinion, Baxter and Bayer, significantly strengthening its portfolio and its ability to deliver complete solutions for clients.

**Issued for and on behalf of LAC MED BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.
For media and investor relations enquiries, please contact:**

Mr. Terence Loo terence@aquilas.com.my

T:03-2711 1391/ M: 012-629 5618

Mr. Tee Wei Keat weikeat@aquilas.com.my

T:03-2711 1391/ M: 012-309 5448